Actively Recruiting
Study of Silkworm Pupa Powder to Improve Nutrition and Cognitive Function in Alzheimers Disease Patients Aged 50 to 90
Led by Zhejiang Hospital · Updated on 2026-01-02
200
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating whether silkworm pupa powder can improve the nutritional status, sarcopenia, frailty, quality of life, and cognitive function in patients with Alzheimers disease. This prospective, double-blind, randomized controlled clinical study aims to compare the effects of silkworm pupa powder against a placebo in people aged 50 to 90 years who meet specific Alzheimers disease diagnostic criteria. Participants will take either silkworm pupa powder or a placebo twice daily with warm water before meals for three months. Each dose consists of two packets 12 grams each taken two times a day. The study will include checkups and tests every four weeks during the treatment period to monitor effects and safety. During the study, participants will visit the clinic every four weeks for assessments including blood tests measuring hemoglobin, albumin, serum prealbumin, vitamin D, alkaline phosphatase, parathyroid hormone, and calcitonin. Imaging tests such as abdominal CT scans and head MRI will also be performed. Researchers will evaluate sarcopenia using diagnostic criteria and cognitive function with tools like the Mini-Mental State Examination and Clinical Dementia Rating. Participants will keep a daily diary of their consumption, and safety and health will be closely monitored throughout the trial lasting at least 12 weeks.
CONDITIONS
Brief Title
A Study of Silkworm Pupa Powder Intervention in the Nutritional Status of Patients With Alzheimer's Disease.
Research Team
S
Song Qiao
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
